Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

CompletedOBSERVATIONAL
Enrollment

610

Participants

Timeline

Start Date

July 28, 2022

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Heart Failure
Interventions
DRUG

JARDIANCE®

JARDIANCE® film-coated tablets 10mg

Trial Locations (21)

10326

Dongguk University Medical Center, Goyang-si, Gyeonggi-do

10380

Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do

11765

The Catholic University of Korea, Uijeongbu ST. Mary's Hospital, Uijeongbu-si, Gyeonggi-do

14068

Hallym University Medical Center, Anyang-si, Gyeonggi-do

24289

Kangwon National University Hospital, Chuncheon-si, Gangwon-do

35015

Chungnam National University Hospital, Daejeon

41944

Kyungpook National University Hospital, Daegu

42415

Yeungnam University Medical Center, Daegu

47392

Inje University Busan Paik Hospital, Busan

48108

Inje University Haeundae Paik Hospital, Busan

49241

Pusan National University Hospital, Busan

50612

Pusan National University Yangsan Hospital, Busan

54907

Jeonbuk National University Hospital, Jeonju-si, Jeollabuk-do

61469

Chonnam National University Hospital), Gwangju

02841

Korea University Anam Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

05368

VHS Medical Center, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

07061

Seoul National University Boramae Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05236673 - Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure | Biotech Hunter | Biotech Hunter